Why the study?
Does trimetazidine added to pharmacological treatment reduce all-cause mortality in patients with systolic heart failure?
Population
326 patients with systolic heart failure pooled from 3 RCTs
Comparison
Trimetazidine added to pharmacological heart… vs Control group receiving pharmacological heart…
Design
Meta-analysis
Follow-up
12 to 48 months
Authors
Loading...
Supports trimetazidine addition in systolic HF; confirms mortality benefit in Level 1 meta-analysis.
Does trimetazidine added to pharmacological treatment reduce all-cause mortality in patients with systolic heart failure?
Trimetazidine added to standard pharmacological therapy significantly reduces all-cause mortality in patients with systolic heart failure.
Grajek et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: